These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34247968)

  • 1. Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction.
    Belarte-Tornero LC; Mojón D; Solé-González E; Ruiz-Bustillo S; Valdivielso-More S; Farré N
    Rev Esp Cardiol (Engl Ed); 2021 Dec; 74(12):1117-1119. PubMed ID: 34247968
    [No Abstract]   [Full Text] [Related]  

  • 2. The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    Voordes GHD; Heerspink HJL; Ter Maaten JM
    Eur J Heart Fail; 2022 May; 24(5):804-806. PubMed ID: 35415946
    [No Abstract]   [Full Text] [Related]  

  • 3. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
    Raschi E; Diemberger I; Sabatino M; Poluzzi E; De Ponti F; Potena L
    Expert Opin Pharmacother; 2022 Feb; 23(3):303-320. PubMed ID: 35050813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age.
    Abumayyaleh M; El-Battrawy I; Kummer M; Pilsinger C; Sattler K; Kuschyk J; Aweimer A; Mügge A; Borggrefe M; Akin I
    Future Cardiol; 2021 Sep; 17(6):1131-1142. PubMed ID: 33733830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction.
    Slawson DC
    Am Fam Physician; 2022 Jun; 105(6):Online. PubMed ID: 35704816
    [No Abstract]   [Full Text] [Related]  

  • 7. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A narrative review on sacubitril/valsartan and ventricular arrhythmias.
    Wei Z; Zhang M; Zhang Q; Gong L; Wang X; Wang Z; Gao M; Zhang Z
    Medicine (Baltimore); 2022 Jul; 101(27):e29456. PubMed ID: 35801732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Solomon SD; McMURRAY JJV
    J Card Fail; 2021 Jun; 27(6):693-695. PubMed ID: 33872760
    [No Abstract]   [Full Text] [Related]  

  • 12. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
    Sinha A; Patel RB
    Eur J Heart Fail; 2023 Jan; 25(1):95-97. PubMed ID: 36445011
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Li Z; Greiner MA; Lippmann SJ; Hardy NC; Shen X; Stampehl M; Mentz RJ; Allen LA; Peterson PN; Fonarow GC; O'Brien EC; Greene SJ
    Circ Heart Fail; 2023 Jan; 16(1):e010176. PubMed ID: 36314141
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Application of Sacubitril/Valsartan in Heart Failure.
    Liu X; Zhong L
    Am J Ther; 2021 Apr; 28(4):e511-e513. PubMed ID: 33852477
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
    Dereli S; Kılınçel O; Çerik İB; Kaya A
    Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.